Dataset Information


Improved grip myotonia in a patient with myotonic dystrophy type 1 following electroacupuncture therapy: A CARE-compliant case report.

ABSTRACT: RATIONALE:Myotonic dystrophy type 1 (DM1) is an autosomal-dominant disorder associated with a short life expectancy and various symptoms, including grip myotonia. Even though grip myotonia decreases quality of life, activities of daily living (ADLs), and work performance, very few interventions provide symptomatic relief. PATIENT CONCERNS:In this case report, we present a patient with DM1 and gradually worsening grip myotonia. A 35-year-old woman developed grip myotonia at age 27. She had no underlying diseases or family history of relevant conditions, including DM1. She was unresponsive to medication for several years. DIAGNOSIS:Her symptoms gradually worsened, and she was finally diagnosed with DM1 via genetic, neurologic, and laboratory testing in a tertiary hospital at age 32. She tried several medication therapies; however, she stopped medication at age 34 due a perceived poor response and several adverse events. INTERVENTION:At the age of 35, she underwent 29 sessions (10?minutes per session) of electroacupuncture therapy on TE9 acupuncture point with 120?Hz electrical stimulation over 3 months. OUTCOMES:After 3 months, relaxation time after maximal voluntary isometric contraction decreased from 59 to 2?seconds with treatment. Her Michigan Hand Outcomes Questionnaire score improved (total score, 66.6-75.9; ADL sub-score, 59.7-73.6; function sub-score, 70-90; satisfaction sub-score, 75-91.7). Her Measure Yourself Medical Outcome Profile 2 score also improved from 4.33 to 2. There were no serious adverse events. LESSONS:Electroacupuncture is a potential treatment modality and produced an immediate antimyotonic effect, and cumulative long-term treatment effect, in a patient with DM1 and grip myotonia. Other notable treatment outcomes included improving relaxation time, hand function, ADLs, and overall satisfaction. Electroacupuncture is a potential treatment modality for patients with DM1 and grip myotonia. Further prospective clinical studies are warranted to confirm this hypothesis.


PROVIDER: S-EPMC7489697 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC2871004 | BioStudies
2018-01-01 | S-EPMC6197259 | BioStudies
2020-01-01 | S-EPMC7452101 | BioStudies
1000-01-01 | S-EPMC3718203 | BioStudies
2019-01-01 | S-EPMC6726129 | BioStudies
2016-01-01 | S-EPMC4704483 | BioStudies
1000-01-01 | S-EPMC3533547 | BioStudies
1000-01-01 | S-EPMC3701899 | BioStudies
2019-01-01 | S-EPMC6640894 | BioStudies
2013-01-01 | S-EPMC4006279 | BioStudies